Business Wire

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other ...

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
TMCnet

ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange -- A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs

ASGCT–OTXL joint venture platform goes live with demo at ASGCT 2026 Annual Meeting and applications opening this month for qualified Asset listings BOSTON, May 14, 2026 /PRNewswire/ -- The American ...
GEN - Genetic Engineering and Biotechnology News

ASGCT 2026: Rare Instance of AAV Integration into Human Genome Linked to Brain Tumor

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
Business Wire

ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid ...

Serif Biomedicines Presents Data at ASGCT 2026 Demonstrating the Potential of Modified DNA as a New Class of Genetic Medicines

Serif Biomedicines Presents Data at ASGCT 2026 Demonstrating the Potential of Modified DNA as a New Class of Genetic Medicines ...
GEN - Genetic Engineering and Biotechnology News

“It Was Not a Cure”: Musunuru Cautions ASGCT on Baby KJ Promise

One of the winners of the 2026 ASGCT Catalyst Award, Kiran Musunuru, MD, PhD, delivered a sobering lecture on the legacy of ...
PharmTech

Capsida Previews Its Oral and Poster Presentations for ASGCT 2025

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing. Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced ...
PharmiWeb

Acuitas Therapeutics Highlights In Vivo CAR T Cell Engineering and Ionizable Lipid Quality Attributes at the 2026 ASGCT Annual Meeting

Targeted extended circulation LNP incorporating DARPins achieved complete B cell depletion in nonhuman primates through highly specific in vivo CD8+ T cell engineeringRobust study quantifies ...

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations highlight Voyager’s ...

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at ...

Encoded Therapeutics Presents New Preclinical Data at ASGCT 2026 Highlighting Precision Vector Engineering Across Neurology Programs

Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present new preclinical data across ...
Morningstar

ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange — A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs

ASGCT–OTXL joint venture platform goes live with demo at ASGCT 2026 Annual Meeting and applications opening this month for qualified Asset listings The platform is being demonstrated live during the ...